Clinical trials: T2DM (Type 2 Diabetes Mellitus)
Type 2 Diabetes Mellitus (T2DM)
Validity and Reliability of Mixed Reality-Based Functional Mobility Tests in Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM) is a multifaceted metabolic disease associated not only with impaired glycemic control but also with reductions in muscle strength, balance, functional mobility, and walking performance.
- Trial name
- NCT07649967
- Testing
- Mixed Reality-Based Functional Performance Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Selcuk University
Obesity, Nutritional Deficiency
Comparison of Weight Loss and Nutritional Deficiency After One Anastomosis Gastric Bypass at 150, 170, and 200 cm From the Duodenojejunal Junction
This study is a randomized clinical trial comparing the effects of One Anastomosis Gastric Bypass performed at three different distances from the duodenojejunal junction-150 centimeters, 170 centimeters, and 200 centimeters-on…
- Conditions
- Obesity, Nutritional Deficiency, Type 2 Diabetes Mellitus (T2DM), Bariatric Surgery (Gastric Bypass)
- Trial name
- NCT06664099
- Testing
- One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction), One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction), One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Weight Management
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2…
- Trial name
- NCT06562907
- Testing
- GS-4571, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
This study aims to investigate whether a class of diabetes medications called GLP-1 receptor agonists (GLP-1RA), specifically semaglutide or polyethylene glycol loxenatide, can improve heart-related nerve damage in people with…
- Trial name
- GLP-1-CAN (NCT07558863)
- Testing
- GLP-1 Receptor Agonists
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diabetes Mellitus, Type 2
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
GLP-1 receptor agonists (GLP-1 RA) is group of antidiabetic agents very effective in lowering the plasma glucose concentration in T2DM patients .
- Trial name
- NCT04135287
- Testing
- GLP-1 receptor agonist
- Where
- Kuwait
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Dasman Diabetes Institute
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM)
Adiponectin in Patients With Metabolic Disorders
Background. Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with insulin resistance.
- Trial name
- NCT07539584
- Testing
- SGLT2 inhibitor, GLP-1 RA
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Type 2 Diabetes Mellitus
A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
Primary Objective: To assess the mean change in HbA1c (glycated haemoglobin). Secondary Objectives: To evaluate the efficacy and safety of the titration of insulin glargine U300 in terms of: Targeted HbA1c; Targeted fasting self…
- Trial name
- EASE (NCT02954692)
- Testing
- INSULIN GLARGINE (U300), metformin, sulfonylurea
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Sanofi
Type 2 Diabetes (T2DM)
Implementing WHO HEARTS-D Guidelines in Bangladesh for Diabetes Control and Prevention
Type-2 diabetes (T2D) is rising at an alarming rate in the low- and middle-income countries (LMIC). This rapid increase in the T2D burden has a particular impact on cities, where more than half the LMIC populations currently live…
- Trial name
- T2D IR (NCT07155902)
- Testing
- The community-to-facility integrated strategy
- Volunteers
- 5,000 people
- Sponsor
- Florida International University
Type 2 Diabetes Mellitus
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and administered twice daily (BID) on circulating glucose…
- Trial name
- NCT01804842
- Testing
- Met DR
- Volunteers
- 26 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Type 2 Diabetes Mellitus (T2DM)
Comparison of Thrice-Daily Premixed Human Insulin With Basal-Bolus Therapy Among Patients With Poorly Controlled Type 2 Diabetes Mellitus
The goal of this cross-over study is to learn if thrice-daily (TDS) premixed human insulin (PHI) is as useful as basal-bolus (BB) therapy as an intensification treatment in people with poorly controlled type 2 diabetes mellitus…
- Trial name
- NCT06855615
- Testing
- Mixtard® 30 TDS, Insulatard® once daily and thrice daily prandial Actrapid®
- Where
- Malaysia
- Volunteers
- 44 people
- Sponsor
- Hospital Sultanah Aminah Johor Bahru
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus
Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a considered one of the main global health challenges; the vascular endothelium plays an important role in vascular dysfunction in DM; Hyperglycemia induced by it is recognized as the main…
- Trial name
- NCT04195243
- Testing
- Dapagliflozin Pill, Empagliflozin Pill
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Diabetes, Diabetes Mellitus, Type 2
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
- Trial name
- NCT03531905
- Testing
- Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet
- Where
- 4 sites in United States
- Volunteers
- 242 people
- Sponsor
- Esperion Therapeutics, Inc.
Atherosclerotic Cardiovascular Disease, Subclinical Disease and/or Syndrome
Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM)
Background: Type 2 Diabetes Mellitus (T2DM) is associated with an increased burden for cardiovascular disease (CVD). Multifactorial interventions are necessary to reduce the CV risk in T2DM.
- Trial name
- EURDSS (NCT01353066)
- Testing
- Intensive Medical Treatment, IMM+Roux-en-Y Gastric Bypass (RYGBP)
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Hospital Clinic of Barcelona
Diabetes Mellitus, Type 2
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)
To investigate the glycosylated hemoglobin (HbA1c) control of Glimepiride (AMARYL) as OAD initiation mono-therapy in type 2 diabetic patients in China.
- Trial name
- GREAT (NCT00908921)
- Testing
- GLIMEPIRIDE
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Sanofi
Diabetes
Duodenal Exclusion for the Treatment of T2DM
Evaluation of duodenal exclusion procedure for the treatment of T2DM
- Trial name
- NCT00456352
- Testing
- duodenal exclusion
- Where
- Brazil
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Type 2 Diabetes
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
This study is a multicenter, randomized, double-blind, placebo-controlled , phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus placebo in subjects with T2DM inadequate glycemic control with diet…
- Trial name
- NCT07394114
- Testing
- HDM1005 1, HDM1005 2
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus.
- Trial name
- PICT2RE (NCT03797885)
- Testing
- No treatment given
- Where
- 14 sites in Portugal
- Volunteers
- 730 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
The Correlation Between the Retrobulbar Hemodynamics and Intrarenal Hemodynamics in T2DM Patients During the Early Period
Objective: The main target of this study was to research the early changes of retrobulbar and intrarenal hemodynamics, then to research the correlation between them in type 2 diabetes (T2DM) patients without diabetic kidney…
- Trial name
- NCT02805543
- Testing
- Color doppler imaging
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Fourth People's Hospital of Shenyang